Neurocrine Biosciences, Inc.
US ˙ NasdaqGS ˙ US64125C1099

SecurityNBIX / Neurocrine Biosciences, Inc.
InstitutionCALVERT VARIABLE SERIES INC - Calvert VP SRI Mid Cap Portfolio
Latest Disclosed Ownership2,977 shares
Latest Disclosed Value $ 374,179
CALVERT VARIABLE SERIES INC - Calvert VP SRI Mid Cap Portfolio ownership in NBIX / Neurocrine Biosciences, Inc.

On August 25, 2025 - CALVERT VARIABLE SERIES INC - Calvert VP SRI Mid Cap Portfolio filed a NPORT-P form disclosing ownership of 2,977 shares of Neurocrine Biosciences, Inc. (US:NBIX) valued at $374,179 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 2,977 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $491,532 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-25 2025-06-30 NP Neurocrine Biosciences EC US64125C1099 2,977 0 0.00 374 13.68 1.5773
2025-05-28 2025-03-31 NP Neurocrine Biosciences EC US64125C1099 2,977 0 0.00 329 -18.97 1.3367
2025-02-19 2024-12-31 NP Neurocrine Biosciences EC US64125C1099 2,977 777 35.32 406 60.47 1.5964
2024-11-27 2024-09-30 NP Neurocrine Biosciences EC US64125C1099 2,200 1,111 102.02 253 69.80 0.9609
2024-08-20 2024-06-30 NP Neurocrine Biosciences EC US64125C1099 1,089 0 0.00 150 -0.67 0.6045
2024-05-28 2024-03-31 NP Neurocrine Biosciences EC US64125C1099 1,089 0 0.00 150 4.90 0.5602
2024-02-02 2023-12-31 NP Neurocrine Biosciences EC US64125C1099 1,089 -1,805 -62.37 143 -47.23 0.5553
2022-05-27 2022-03-31 NP Neurocrine Biosciences EC US64125C1099 2,894 -2,332 -44.62 271 -39.10 0.8343
2022-02-28 2021-12-31 NP Neurocrine Biosciences EC US64125C1099 5,226 -259 -4.72 445 -15.40 1.2058
2021-11-24 2021-09-30 NP Neurocrine Biosciences EC US64125C1099 5,485 0 0.00 526 -1.31 1.4528
2021-08-19 2021-06-30 NP Neurocrine Biosciences EC US64125C1099 5,485 1,323 31.79 534 31.93 1.4365
2021-05-28 2021-03-31 NP Neurocrine Biosciences EC US64125C1099 4,162 1,498 56.23 405 58.43 1.1251
2021-02-16 2020-12-31 NP Neurocrine Biosciences EC US64125C1099 2,664 2,664 255 0.7121
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.